Free tool
FAERS Monitor: Lo Loestrin Fe
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022501 or its brand name (Lo Loestrin Fe, Ethinyl Estradiol, Norethindrone Acetate). Reports on generic versions are filed under their own applications.
Reports
3,223
Serious
812
25% of reports
Hospitalization
254
Death reported
11
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use373
- amenorrhoea220
- nausea200
- headache163
- drug ineffective158
- metrorrhagia156
- anxiety147
- fatigue139
- depression121
- menstruation irregular108
- product dose omission issue107
- dizziness104
- inappropriate schedule of product administration104
- pain96
- menorrhagia80
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 4 |
| 2011 | 12 |
| 2012 | 45 |
| 2013 | 28 |
| 2014 | 50 |
| 2015 | 246 |
| 2016 | 437 |
| 2017 | 254 |
| 2018 | 367 |
| 2019 | 366 |
| 2020 | 327 |
| 2021 | 218 |
| 2022 | 212 |
| 2023 | 224 |
| 2024 | 157 |
| 2025 | 167 |
| 2026 | 109 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,936 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| amenorrhoeaSignal | 220 | 82.9 | 72.9 | 17,510 |
| metrorrhagiaSignal | 156 | 60.2 | 51.7 | 8,954 |
| menorrhagiaSignal | 80 | 26.7 | 21.5 | 1,946 |
| menstruation irregularSignal | 108 | 26.4 | 21.9 | 2,608 |
| inappropriate schedule of product administrationSignal | 104 | 3.8 | 3.1 | 210 |
| depressionSignal | 121 | 3.5 | 2.9 | 213 |
| anxietySignal | 147 | 3.4 | 2.9 | 246 |
| off label useSignal | 373 | 2.8 | 2.5 | 442 |
| product dose omission issueSignal | 107 | 2.4 | 2.0 | 85 |
| headache | 163 | 1.7 | 1.5 | 47 |
| nausea | 200 | 1.6 | 1.4 | 52 |
| dizziness | 104 | 1.4 | 1.1 | 10 |
| fatigue | 139 | 1.2 | 1.0 | 3 |
| pain | 96 | 1.0 | 0.8 | 0 |
| drug ineffective | 158 | 0.8 | 0.7 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.